Biogen Inc.

BIIB · Nasdaq · ·

Comparar

US$ 253,51+1,2%fechamento 13 de nov.

Números até 30 de setembro de 2026, do 10-Q arquivado em 28 de outubro de 2026

1W: +2,1%
1M: +8,9%

Ações Biogen Inc. (BIIB) — é um bom negócio? — InspectStocks

Biogen Inc.

BIIB · Nasdaq · ·

Comparar

US$ 253,51+1,2%fechamento 13 de nov.

Números até 30 de setembro de 2026, do 10-Q arquivado em 28 de outubro de 2026

1W: +2,1%
1M: +8,9%

Just reported

Q3 2026 results

From Biogen's results release of 28 de outubro de 2026; its quarterly report has since been filed.

Revenue
Actual
US$ 2,8B
+11% y/y
+2,5% q/q
Guided
—
No guide given
EPS, GAAP
Actual
-US$ 0,14
Guided
—
No guide given

Company outlook

Full year 2026

EPS, adjustedUS$ 12,20 – US$ 13,00First given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Biogen is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Curadoria
Biotech
Por InspectStocks · 19 companies
Drug developers with approved medicines, built mainly on biologic and genetic science.
Preço, 1 ano
+26,8%
Receita, 1 ano
+12,9%
+13
A 8B 4C 5D 1F 1

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

All 19 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Como ganha dinheiro

Sales of prescription medicines72%
Anti-CD20 medicine royalties and profit shares18%
Contract manufacturing, royalties and related revenue8%
Alzheimer’s medicine collaboration2%

As participações na receita são estimativas para nine months ended September 30, 2026, não números de um relatório oficial.

Concorre com

LLYEli Lilly and Company
A
Tamanho
US$ 1,36T
Margem
31,9%
RHHBYRoche Holding AG
NVSNovartis AG
A
Tamanho
US$ 306,3B
Margem
-0,1%

O que vende6

SPINRAZA
An injected medicine for spinal muscular atrophy, a disease that causes muscle weakness.
TYSABRI
An infusion medicine for relapsing multiple sclerosis.
LEQEMBI
An antibody medicine for early Alzheimer’s disease, developed and sold with Eisai.

Mostrar mais 3

SKYCLARYS
A medicine for Friedreich ataxia, an inherited disease that affects movement and coordination.
SYFOVRE
An eye injection for geographic atrophy, a disease that can cause central vision loss.
EMPAVELI
A medicine for a rare blood disorder and certain rare kidney diseases.

Quem compra4

Wholesale distributors buy medicines in bulk for resale; a pair of distributors together accounted for 43.9% of gross product revenue (FY 2025, high).
Specialty pharmacies and specialty distributors handle medicines that require specific storage, delivery or patient support.
Hospitals, clinics and physicians prescribe or administer Biogen medicines and help patients obtain them.
Government health programs and private insurers cover or reimburse the cost of many treatments.

Em que se apoia e o que pode quebrá-lo

Do que o negócio depende

1Biogen relies on collaborators for some medicines’ development, manufacturing or sales, including Eisai, Ionis, Genentech, Supernus and Samsung Bioepis.
2A pair of wholesale distributors accounted for 43.9% of gross product revenue (FY 2025, high).
3Sales depend on regulatory approval, continued patent or other market protection, and coverage and reimbursement from government programs and private insurers.

O que pode dar errado

1Generic and biosimilar medicines, as well as newer competing treatments, can reduce sales or prices; generic versions of TECFIDERA and a biosimilar version of TYSABRI already compete with those products.
2Clinical studies can fail, take longer than planned or lead regulators to reject a medicine, limiting revenue from new products and additional uses of existing medicines.
3Changes to drug-price rules, insurance coverage or reimbursement can restrict patient access or lower the amount Biogen receives for its medicines.

Demonstrações financeiras completas →

Sobre a Biogen Inc.

Biogen discovers, develops and sells medicines for neurological, immune-system and rare diseases. Its products include treatments for multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease and certain eye, kidney and blood disorders. It develops and commercializes some medicines with other drug companies, sharing costs, sales or profits under those agreements.

Sede: Cambridge, Massachusetts
Fundada em: 1978
Listada em: NASDAQ
Fim do exercício: December 31

Construído a partir dos próprios documentos de Biogen Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.

Just reported